Phase II trial of 4'-epidoxorubicin in advanced gastrointestinal tumor

Fourteen Chinese patients with histologically proven advanced gastrointestinal tumors underwent a phase II 4'-epidoxorubicin trial. 6 out of 14 (42%) patients showed static response and the rest showed progression of disease during treatment. The treatment was fairly well tolerated with a mild to moderate degree of nausea, vomiting, alopecia and hematological toxicity.